Jay Seigel
Psychiatric/Mental Health · New London, CTNPI 1447416086
Payments from drug & device makers
Across 100 payments — averaging $34.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$725
- Supernus Pharmaceuticals, Inc.$565
- Alkermes, Inc.$430
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$419
- AbbVie$405
- Neurocrine Biosciences, Inc.$152
- plus $746 from 12 others
What the payments were for
- Consulting fees$72521%
- Food & beverage$2,66577%
- Education$522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,442 in reported general payments places this provider in the 85th percentile of 679 psychiatric/mental health providers in Connecticut.
See all psychiatric/mental health providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 34 | $25,035 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $7,243 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 13 | $2,114 |
| Lurasidone Hcl | 25 | $1,375 |
| Dextroamphetamine Sulfate | 12 | $1,262 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 37 | $1,222 |
| Duloxetine Hcl | 110 | $1,145 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $988 |
| Clonazepam | 63 | $860 |
| Lamotrigine | 52 | $766 |
| Bupropion XlBupropion Hcl | 48 | $755 |
| Oxcarbazepine | 14 | $721 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 51 | $678 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $601 |
| Lorazepam | 55 | $508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $21 | $32,27854 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 679 psychiatric/mental health providers in Connecticut.
Other psychiatric/mental health in New London
- William KornegayNew London$7K
- Nancy OlsonNew London$5K
- Cristina MeehanNew Britain$224K
- Samantha MrazBridgeport$87K
- Philip FrickManchester$31K
- Gia SantoroWest Haven$25K
- Donna DraperDanbury$19K
- Zahida SairitupaDanbury$19K
- Hui HuNorwich$19K
- Patrick GagnonMilford$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.